Upstream Bio Reports Positive Top-line Results From Phase 2 VIBRANT Study
(RTTNews) - Upstream Bio, Inc. (UPB) Tuesday announced positive top-line results from Phase 2 VIBRANT study evaluating verekitug in people with chronic rhinosinusitis with nasal polyps.
The study met its primary goal showing statistically significant reduction in endoscopic nasal polyp score (NPS). The study also showed a meaningful reduction in nasal congestion score (NCS)
Further, Verekitug was generally well tolerated, demonstrating a favorable safety profile consistent with previous studies, with no serious adverse events observed.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.